Novel debiased data set CDPN improves generalization and virtual screening performance in compound-protein interactions using a web server.
Accurate prediction of compound-protein interactions (CPIs) is critical for drug discovery, but existing data sets often suffer from biases that hinder model generalization. Here, we first highlighted that over-represented molecular scaffolds and imbalanced label distributions can lead to machine learning shortcuts. While existing debiasing approaches often compromise data set diversity, we present Clustering-based Down-sampling and Putative Negatives (CDPN), a novel protocol for constructing a debiased CPI benchmark. CDPN mitigates biases through compound Cluster-level Down-sampling and generates Putative Negatives from unexplored chemical spaces, ensuring balanced label distributions. Using CDPN, we systematically benchmark deep learning-based CPI models, with a particular focus on protein language models. Although systematic evaluation on PDBbind reveals critical limitations in attention interpretability, thorough ablation studies on the CDPN data set identify superior models such as KPGT-Ankh, which exhibits enhanced generalization and virtual screening performance. The top-performing models from benchmark were also integrated into DeepSEQreen, a no-code web server designed to facilitate community feedback and broader accessibility.
No takes yet. Share an insight, caveat, or question.
Hao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: